Jing-Feng Zong

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The gold standard endpoint in trials of locoregionally advanced nasopharyngeal carcinoma (NPC) is overall survival (OS). Using data from a phase III randomized trial, we evaluated whether progression-free survival (PFS), failure-free survival (FFS), distant failure-free survival (D-FFS) or locoregional failure-free survival (LR-FFS) could be reliable(More)
  • 1